CC
BMY icon

Clearline Capital’s Bristol-Myers Squibb BMY Stock Holding History

Clearline Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-56,932
Closed -$3.07M – 48
2016
Q3 		$3.07M Buy
+56,932
New +$3.66M 0.96% 31

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Clearline Capital's BMY Position: Q4 2016 in Review

Clearline Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2016, closing a stake of 56,932 shares — an estimated $3.07M sold.

Clearline Capital first reported a position in BMY in Q3 2016 and held it in 1 quarter. The position peaked at $3.07M in Q3 2016. 1,601 funds tracked by Wall St. Rank hold BMY as of Q4 2016.

  • Clearline Capital reported no remaining Bristol-Myers Squibb position as of Q4 2016 after selling out during the quarter.
  • Clearline Capital sold 56,932 Bristol-Myers Squibb shares in Q4 2016, an estimated $3.07M.
  • Clearline Capital first reported a position in Bristol-Myers Squibb in Q3 2016 and held it in 1 quarter.
  • Clearline Capital's Bristol-Myers Squibb position peaked at $3.07M in Q3 2016.
  • 1,601 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2016.

Based on Clearline Capital's 13F filing for Q4 2016, filed 14 Feb 2017.